AuntMinnie

SEPTEMBER 25, 2024

Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert. Ultimately, there are “many unknowns” to be explored in the next few months – implications regarding the unknown cost of new diagnostic radiopharmaceuticals, for instance – and the ASNC is in continuing talks with the CMS.

Nuclear Medicine 64

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 64

Radiology Business

JULY 12, 2024

For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.

Radiopharmaceuticals 83

Radiopharmaceuticals Diagnostic Imaging 83

Imaging Technology

NOVEMBER 7, 2024

Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.

Nuclear Medicine 97

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 97

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Imaging Medicare 122

Imaging Technology

JULY 5, 2024

Lantheus intends to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025. 68Ga-DOTA-RM2 will be used as a companion diagnostic. mtaschetta-millane Fri, 07/05/2024 - 06:00 July 5, 2024 — Lantheus Holdings, Inc. ,

Diagnostic 105

Diagnostic Radiopharmaceuticals Disease IT 105

AuntMinnie

NOVEMBER 4, 2024

Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. Although the 2025 MPFS calls for an overall 2.9% The change to the MPFS conversion factor reflects the 0% update required by statute for 2025, the expiration of the 2.9%

Radiation Oncology 80

Radiation Oncology Nuclear Medicine Medicare Imaging 80

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52